Results 311 to 320 of about 132,194 (344)

Photophysics and photochemistry of fluoroquinolones

Chemical Society Reviews, 2003
AbstractFor Abstract see ChemInform Abstract in Full Text.
A Albini, S Monti
openaire   +4 more sources

Fluoroquinolones, tuberculosis, and resistance [PDF]

The Lancet Infectious Diseases, 2003
Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential first-line agents and are under study for this indication.
Amy Sarah Ginsburg, Jacques H. Grosset, William R. Bishai   +2 more
openaire   +2 more sources

Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.

American Journal of Health-System Pharmacy, 2014
PURPOSE Results of a pharmacoepidemiologic evaluation of fluoroquinolone-associated hepatotoxicity using national hospital admissions data on Veterans Affairs (VA) patients are reported.
T. Alshammari, E. Paul Larrat, H. Morrill, A. Caffrey, B. Quilliam, K. LaPlante   +5 more
semanticscholar   +1 more source

Gemifloxacin: a new fluoroquinolone

Expert Opinion on Pharmacotherapy, 2004
Gemifloxacin is a dual targeted fluoroquinolone with potent in vitro activity against Gram-positive, -negative and atypical human pathogens--pathogens considered to be important causes of community-acquired respiratory tract infections. Gemifloxacin demonstrates impressive minimal inhibitory concentrations (MIC 90 ) values against clinical isolates of ...
Bayan Missaghi, Joseph M Blondeau
openaire   +2 more sources

Safety of fluoroquinolones in paediatrics

Expert Opinion on Drug Safety, 2002
In the last few years, there has been increasing pressure to use fluoroquinolones in paediatric patients, since these antibiotics offer the advantage of an oral treatment regimen on an out-patient basis. However, even although this class of antibiotics generally remains well-tolerated, the restriction of fluoroquinolone use in children on a ...
Cuzzolin L, FANOS, VASSILIOS
openaire   +5 more sources

The Role of the Fluoroquinolones

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1992
Over the past decade, the quinolone antimicrobial class has enjoyed a renaissance with the emergence of the fluoroquinolone subclass. Norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin have the advantages of broad antimicrobial activity profiles including gram‐positive and ‐negative aerobes, favorable pharmacokinetic profiles including ...
openaire   +3 more sources

Fluoroquinolones in the treatment of meningitis

Current Infectious Disease Reports, 2003
The continuous increase of resistant pathogens causing meningitis has limited the efficacy of standard therapeutic regimens. Due to their excellent activity in vitro and their good penetration into the cerebrospinal fluid (CSF), fluoroquinolones appear promising for the treatment of meningitis caused by gram-negative microorganisms, ie, Neisseria ...
Martin G. Täuber, Philippe Cottagnoud
openaire   +3 more sources

Seizures Associated with Fluoroquinolones

The Annals of Pharmacotherapy, 2001
OBJECTIVE: To report two cases of seizures following administration of levofloxacin and ciprofloxacin. CASE SUMMARY: A 75-year-old white woman admitted to the hospital was prescribed levofloxacin for ischemic toes. After receiving three doses of oral levofloxacin, the patient experienced a seizure.
Janine M Kushner, Clyde R Snyder, Howard J. Peckman   +2 more
openaire   +3 more sources

Fluoroquinolones for the eye

Drug and Therapeutics Bulletin, 1994
Two fluoroquinolone antibiotics, ciprofloxacin (Ciloxan - Alcon) and ofloxacin (Exocin - Allergan), are available in the UK as topical preparations for the eye.* Ciprofloxacin eyedrops are licensed for the treatment of "corneal ulcers and superficial infections of the eye", and ofloxacin eyedrops for "external ocular infections (such as conjunctivitis ...
openaire   +2 more sources

Pharmacokinetics and Pharmacodynamics of Fluoroquinolones

Drugs, 1999
The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg. There is considerable variation in elimination pattern between fluoroquinolone agents, ranging from predominant renal excretion to extensive hepatic metabolism.
openaire   +4 more sources